Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda’s Actos drug approved

Takeda’s Actos drug approved

24th March 2009

Takeda’s Actos has been approved to treat type two diabetes.

It directly targets insulin resistance by improving the sensitivity to the substance in muscles, the liver and fat cells.

The authorisation of the concomitant therapy now means it can be administrated to those patients who can control their condition adequately through careful management of diet, exercise and insulin administration.

Actos is designed to be taken orally once a day in adults before or after breakfast. It will normally be consumed in 15 mg doses but – depending on the age, gender and symptoms ? this amount could be increased to 30 mg.

The pharmaceutical company remarked it will continue to maximise the value of Actos.

“[We will] promote development activities that offer a variety of treatment options to patients with type two diabetes and also to healthcare providers,” it asserted.

Yesterday (March 23rd), Takeda announced it had signed an agreement with Wyeth for the product licence for Prostrap to transfer back to the former from the latter in the UK and Ireland.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.